In Chronic Granulomatous Disease (CGD) the white blood cells are unable to produce activated O2 compounds (or anti-oxidants), which normally help a person to fight against infection. Thus, this leads to recurrent life-threatening bacterial and fungal infections. There occurs an excessive accumulation of immune cells into aggregates called granulomas.
Diagnosis is done using a test called flow cytometric respiratory burst assay.
Treatment is with antibiotics, antifungal drugs, and interferon-.
The disease was first described in the 1950s as “a fatal granulomatosus of childhood". More than half of cases of chronic granulomatous disease are transmitted genetically as an X-linked recessive trait. CGD thus occurs only in males. Most of the patients with CGD present during the first 5 years of life. In the rest inheritance is autosomal recessive. No racial predilection is known.
Latest Publication and Research on Chronic Granulomatous DiseaseNocardia brasiliensis vertebral osteomyelitis and epidural abscess. - Published by PubMed
Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease. - Published by PubMed
Pediatric allergy and immunology in Brazil. - Published by PubMed
The role of surgery in the management of patients with refractory chronic granulomatous disease colitis. - Published by PubMed
Neurosarcoidosis: diagnostic approaches and therapeutic strategies. - Published by PubMed